STAA Earnings Prediction
The chart below shows how STAA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, STAA sees a +3.17% change in stock price 10 days leading up to the earnings, and a -4.22% change 10 days following the report. On the earnings day itself, the stock moves by +0.20%. This data can give you a slight idea of what to expect for the next quarter's release.
STAA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
88.59M
10.31%
-10.52%
Gross Margin
77.31%
-2.44%
-2.39%
Operating Margin
6.41%
-18.24%
-46.67%
Net Margin
11.27%
87.83%
51.28%
EPS
0.20
100.00%
33.33%
No Data Available
STAA Earnings Analysis
Staar Surgical Co Corporation (STAA.O) Earnings Conference Call
Positive
Sales Growth Achievement: In the third quarter, we achieved net sales of $88.6 million and double-digit sales growth against the macroeconomic environment that softened in the second half of the quarter, particularly in China.
Market Share Expansion: Our results reflect the increased global adoption and market share gains of EVO ICL lenses, the positive returns on our investments in commercial programs, our customer-focused initiatives, and the global diversity of our business.
Sales Outlook Maintenance: For fiscal year 2024, we are maintaining our financial outlook and continue to anticipate net sales of approximately $340 million to $345 million.
New Experience Center Opening: During the third quarter, we celebrated the grand opening of our new EVO ICL Experience Center at our Lake Forest, Southern California headquarters, which includes cutting-edge technology and workstations for approximately 60 individuals, nearly 10 times the capacity of our previous center.
Americas Sales Growth: In the Americas, we generated sales growth of 14% in the third quarter, with U.S. sales growing 16% year-over-year.
Negative
Q3 Sales Increase: Total net sales for Q3 2024 increased 10% to $88.6 million, up from $80.3 million in the prior year quarter. This increase is largely attributable to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products.
Operating Expenses Increase: Total operating expenses for Q3 2024 increased 10% to $62.8 million, up from $57.3 million in Q3 2023 and down from $66.5 million in Q2 2024. The sequential decrease in operating expenses reflects a shift in the timing of some spend that we now expect to occur in Q4 2024.
Gross Margin Decline Factors: The year-over-year decrease in gross margin was primarily due to reduced unit production that resulted in less absorption of fixed overhead.
Gross Profit Margin Adjustment: For the fully year, we now expect gross profit margin to be approximately 79%, down 1 point from our previous estimate.
Non-Cash Write-Off Impact: We incurred a $1.6 million non-cash write-off related to our former EVO Experience Center.
STAA FAQs
How does STAA typically perform around its earnings report dates?
Is STAAR Surgical Company (STAA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
STAA Earning Call Sentiment
STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
STAA.O
-1.16%Positive
The earnings call presents mixed signals. Financial performance shows growth in sales and net income, but declining gross margins and increased expenses raise concerns. The Q&A reveals challenges in China and the U.S. market, with management hesitant to provide clear guidance. The lack of a shareholder return plan and macroeconomic uncertainties also weigh on sentiment. Despite some positives, such as market share gains, the overall outlook remains uncertain, leading to a neutral prediction for stock price movement.